Why Glaukos Corp. Stock Sank 12.8% in September
After management decided to dial back revenue expectations for 2017, shares of Glaukos (NYSE: GKOS), a medical device maker focused on diseases of the eye, tumbled 13% in September, according to data from S&P Global Market Intelligence.
Glaukos' management team held an investor day in mid-September. Here's a review of the key takeaways from the presentation:
Wall Street responded to the downward guidance by deflating the company's share price.
Source: Fool.com
Novartis AG ADR Aktie
94,20 €
-0,84 %
Die Novartis AG ADR Aktie hat nicht genug Einschätzungen für ein klares Sentiment.
Das Community-Kursziel von 110 € für Novartis AG ADR deutet auf ein leicht positives Wachstumspotenzial gegenüber 94.2 € hin.
